{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:50:27Z","timestamp":1762005027940,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"MyoKardia"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ccl.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T10:35:07Z","timestamp":1540809307000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"37","author":[{"given":"Stephen B.","family":"Heitner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jchf.2018.03.004","article-title":"Global burden of hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.004_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.ccl.2018.08.004_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.281.7.650","article-title":"Clinical course of hypertrophic cardiomyopathy in a regional United States cohort","volume":"281","author":"Maron","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ccl.2018.08.004_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0735-1097(95)00353-3","article-title":"Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population","volume":"26","author":"Cecchi","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ccl.2018.08.004_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJM198903233201201","article-title":"Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population","volume":"320","author":"Spirito","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccl.2018.08.004_bib7","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1161\/01.CIR.92.9.2488","article-title":"Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990","volume":"92","author":"Cannan","year":"1995","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ccl.2018.08.004_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.amjcard.2011.12.027","article-title":"Hypertrophic cardiomyopathy with longevity to 90 years or older","volume":"109","author":"Maron","year":"2012","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.ccl.2018.08.004_bib9","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.jacc.2013.02.079","article-title":"Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy","volume":"61","author":"Feiner","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ccl.2018.08.004_bib10","article-title":"Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy","volume":"6","author":"Finocchiaro","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"13","key":"10.1016\/j.ccl.2018.08.004_bib11","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM199609263351305","article-title":"The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy","volume":"335","author":"Paz","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccl.2018.08.004_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.amjcard.2010.06.061","article-title":"Drink more, and eat less: advice in obstructive hypertrophic cardiomyopathy","volume":"106","author":"Kansal","year":"2010","journal-title":"Am J Cardiol"},{"issue":"22","key":"10.1016\/j.ccl.2018.08.004_bib13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.0000128363.85581.E1","article-title":"Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases","volume":"109","author":"Maron","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ccl.2018.08.004_bib14","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.jacc.2011.10.825","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"58","author":"Gersh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.ccl.2018.08.004_bib15","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force Members","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/hrt.20.1.1","article-title":"Asymmetrical hypertrophy of the heart in young adults","volume":"20","author":"Teare","year":"1958","journal-title":"Br Heart J"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.004_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1996.03540030033028","article-title":"Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles","volume":"276","author":"Maron","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.004_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.csm.2015.03.005","article-title":"Sports and exercise in athletes with hypertrophic cardiomyopathy","volume":"34","author":"Alpert","year":"2015","journal-title":"Clin Sports Med"},{"issue":"8","key":"10.1016\/j.ccl.2018.08.004_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.108.804617","article-title":"Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006","volume":"119","author":"Maron","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2018.08.004_bib20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0002-9149(98)00455-X","article-title":"Predictors of sudden cardiac death in hypertrophic cardiomyopathy","volume":"82","author":"Maki","year":"1998","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.ccl.2018.08.004_bib21","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2003.03.002","article-title":"Does sports activity enhance the risk of sudden death in adolescents and young adults?","volume":"42","author":"Corrado","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.ccl.2018.08.004_bib22","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM200011093431911","article-title":"The paradox of exercise","volume":"343","author":"Maron","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2018.08.004_bib23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjcard.2012.12.018","article-title":"Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy","volume":"111","author":"Reineck","year":"2013","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s10897-018-0218-8","article-title":"Psychological impact of a positive gene result for asymptomatic relatives at risk of hypertrophic cardiomyopathy","volume":"27","author":"Bonner","year":"2018","journal-title":"J Genet Couns"},{"issue":"2","key":"10.1016\/j.ccl.2018.08.004_bib25","doi-asserted-by":"crossref","first-page":"e000484","DOI":"10.1136\/openhrt-2016-000484","article-title":"Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers","volume":"3","author":"Sweeting","year":"2016","journal-title":"Open Heart"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.117.029989","article-title":"Exercise and hypertrophic cardiomyopathy: time for a change of heart","volume":"137","author":"Saberi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2018.08.004_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.07.015","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"250","author":"Dejgaard","year":"2018","journal-title":"Int J Cardiol"},{"issue":"13","key":"10.1016\/j.ccl.2018.08.004_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","article-title":"Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial","volume":"317","author":"Saberi","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2047487313501277","article-title":"Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center","volume":"22","author":"Klempfner","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2018.08.004_bib30","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.amjcard.2013.05.070","article-title":"Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy","volume":"112","author":"Canepa","year":"2013","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2013.03.062","article-title":"Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy","volume":"62","author":"Olivotto","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1378\/chest.14-0084","article-title":"Sleep-disordered breathing in hypertrophic cardiomyopathy: challenges and opportunities","volume":"146","author":"Konecny","year":"2014","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.004_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.smrv.2012.06.006","article-title":"Obstructive sleep apnea and hypertrophic cardiomyopathy: a common and potential harmful combination","volume":"17","author":"Nerbass","year":"2013","journal-title":"Sleep Med Rev"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1751-7133.2010.00196.x","article-title":"Incidence of sleep-disordered breathing in patients with hypertrophic cardiomyopathy","volume":"17","author":"Prinz","year":"2011","journal-title":"Congest Heart Fail"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.004_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000321718","article-title":"Sleep quality and quality of life in patients with hypertrophic cardiomyopathy","volume":"117","author":"Pedrosa","year":"2010","journal-title":"Cardiology"},{"issue":"11","key":"10.1016\/j.ccl.2018.08.004_bib36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.amjcard.2010.01.023","article-title":"Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"105","author":"Konecny","year":"2010","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2018.08.004_bib37","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1378\/chest.14-1498","article-title":"Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy","volume":"147","author":"Konecny","year":"2015","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.004_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14779072.2015.1004314","article-title":"Hypertrophic cardiomyopathy associated with sleep apnea: serious implications and cogent management strategy","volume":"13","author":"Aggarwal","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.genhosppsych.2007.09.005","article-title":"Psychiatric disorders in hypertrophic cardiomyopathy","volume":"30","author":"Morgan","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"10.1016\/j.ccl.2018.08.004_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/GIM.0b013e3181612cc7","article-title":"Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy","volume":"10","author":"Ingles","year":"2008","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/heartasia-2012-010099","article-title":"Depression in patients with hypertrophic cardiomyopathy: is there any relation with the risk factors for sudden death?","volume":"4","author":"Igoumenou","year":"2012","journal-title":"Heart Asia"},{"issue":"9","key":"10.1016\/j.ccl.2018.08.004_bib42","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1540-8159.2010.02770.x","article-title":"Emotional stress triggers symptoms in hypertrophic cardiomyopathy: a survey of the Hypertrophic Cardiomyopathy Association","volume":"33","author":"Lampert","year":"2010","journal-title":"Pacing Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.004_bib43","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajmg.a.32710","article-title":"Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study","volume":"149a","author":"Christiaans","year":"2009","journal-title":"Am J Med Genet A"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.004_bib44","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10897-017-0186-4","article-title":"Examining the psychosocial impact of genetic testing for cardiomyopathies","volume":"27","author":"Wynn","year":"2018","journal-title":"J\u00a0Genet Couns"},{"issue":"2","key":"10.1016\/j.ccl.2018.08.004_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.ccl.2018.08.004_bib46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib47","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.004_bib48","doi-asserted-by":"crossref","first-page":"e004572","DOI":"10.1161\/CIRCHEARTFAILURE.117.004572","article-title":"Evolving story of clinical trials in hypertrophic cardiomyopathy","volume":"11","author":"Elliott","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ccl.2018.08.004_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","article-title":"The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial","volume":"187","author":"Ho","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccl.2018.08.004_bib50","unstructured":"Clinical study to evaluate mavacamten (MYK-461) in\u00a0adults with symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM). (ClinicalTrials.gov Identifier: NCT03470545). Available at: https:\/\/clinicaltrial.gov. Accessed July 16, 2018."},{"key":"10.1016\/j.ccl.2018.08.004_bib51","unstructured":"A phase 2 study of mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) (MAVERICK-HCM) (ClinicalTrials.gov Identifier: NCT03442764). Available at: https:\/\/clinicaltrial.gov. Accessed July 16, 2018."},{"issue":"5492","key":"10.1016\/j.ccl.2018.08.004_bib52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.1.5492.895","article-title":"Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy","volume":"1","author":"Cherian","year":"1966","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.ccl.2018.08.004_bib53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","article-title":"Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol","volume":"38","author":"Flamm","year":"1968","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2018.08.004_bib55","first-page":"A21307","article-title":"Beta-blockers inferior to calcium channel blockers in hypertrophic cardiomyopathy","volume":"136","author":"Gombar","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2018.08.004_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","article-title":"Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression","volume":"3","author":"Ho","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.004_bib57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","article-title":"Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy","volume":"64","author":"Epstein","year":"1981","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccl.2018.08.004_bib58","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in\u00a0obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ccl.2018.08.004_bib59","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9149(88)90268-8","article-title":"Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.ccl.2018.08.004_bib60","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/0002-9149(88)90269-X","article-title":"Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.ccl.2018.08.004_bib61","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM198210143071607","article-title":"Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide","volume":"307","author":"Pollick","year":"1982","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.004_bib62","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0033-0620(05)80036-2","article-title":"Hypertrophic cardiomyopathy","volume":"36","author":"Louie","year":"1994","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.004_bib63","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ccl.2018.08.004_bib64","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","article-title":"Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME)","volume":"68","author":"Gentry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2018.08.004_bib65","first-page":"124","article-title":"Impact of ranolazine on ventricular arrhythmias - A systematic review","volume":"34","author":"Bazoukis","year":"2018","journal-title":"J\u00a0Arrhythm"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865118308634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865118308634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:50:27Z","timestamp":1760007027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865118308634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0733865118308634"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2018.08.004","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}